ClinicalTrials.gg
RecruitingNCT07494045Updated Aug 20, 2026

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

A Phase 2 interventional study of CTAP101 in CKD Stage 3, CKD Stage 4 and Secondary Hyperparathyroidism, sponsored by OPKO Health, Inc.. Recruiting at 5 sites in United States. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Hyperparathyroidism, Secondary · OPKO Health, Inc..

Planned enrollment
8th of 13
40 · median 41
Started
2026
the only one that year
Phase 2
3 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc., this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2, and was the 13th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

1 of the 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc. is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hyperparathyroidism, Secondary by OPKO Health, Inc., or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are:

  1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules
  2. To investigate the safety and tolerability of CTAP101 Capsules

Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.

03

Conditions studied

  • CKD Stage 3
  • CKD Stage 4
  • Secondary Hyperparathyroidism
  • VDI
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet the following criteria to be enrolled in Cohort 1 of this study:

  1. Be 8 to \<18 years of age with a body weight of ≥40 kg.
  2. Be diagnosed with stage 3 or 4 CKD at least six months prior to the screening visit (Visit 1) and have an of ≥15 to \<60 mL/min/1.73m2 at screening.
  3. Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation.
  4. Exhibit during the initial or, if necessary, a screening visit after washout:

    1. Plasma iPTH >85 pg/mL;
    2. Serum Ca \<9.8 mg/dL;
    3. Serum P ≤5.5 mg/dL; and
    4. Serum 25D \<30 ng/mL.
  5. If taking calcitriol or other 1α-hydroxylated vitamin D therapy, be willing to forgo treatment with these agents for the duration of the study and complete a 2-week prior to commencing treatment in the study.
  6. If receiving ≤2,000 IU/day or 50,000 IU/month (1,250 mcg) vitamin D supplementation (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.
  7. If taking >2,000 IU/day of vitamin D supplementation, must discontinue or decrease the dose to ≤2,000 IU/day, maintain that dose for the duration of the study and complete a 2-week washout period prior to commencing treatment in the study.
  8. If taking >1000 mg/day of elemental Ca through Ca-based phosphate binder or antacid therapy, must discontinue or decrease the dose to ≤ 1000 mg/day, maintain that dose for the duration of the study, and complete a 2-week washout period prior to commencing treatment in the study.
  9. If taking any bone metabolism therapy that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.
  10. Willing and able to comply with study procedures and instructions and commit to all study visits for the duration of the study.
  11. Willing and able to safely swallow the CTAP101 capsules whole.
  12. Female participants of must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit.
  13. All female participants of childbearing potential and male participants with female partners of childbearing potential must agree to use effective (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
  14. Each participant or their legal representative must be able to read, understand and sign the ICF.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

  1. Kidney transplant within the 26 weeks preceding screening or kidney transplant rejection within the 26 weeks preceding screening.
  2. No history of parathyroidectomy or planned parathyroidectomy.
  3. History (prior three months) of serum Ca ≥9.8 mg/dL.
  4. Use of calcimimetic or calcifediol therapy within three months prior to consent.
  5. Use of bisphosphonate or denosumab therapy within six months prior to consent.
  6. Known or suspected to any of the constituents in CTAP101 Capsules.
  7. Known previous or concomitant serious illness or medical condition, such as , , significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or abnormal or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.
  8. History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or FU schedule unlikely.
  9. Currently participating in, or has participated in, an interventional/ study within 30 days prior to study screening that in the opinion of the investigator and/or sponsor would interfere with the safety, assessments, and results of this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - Group A

    30 mcg CTAP101 Capsules

    Drug: CTAP101

  • Experimental
    Cohort 1 - Group B

    30 mcg or 60 mcg CTAP101 Capsules

    Drug: CTAP101

Interventions

06

What researchers measure

Primary outcomes

  1. Apparent clearance (CL/F)

    To determine the CL/F of CTAP101 Capsules during and after repeated dosing

    Time frame: Up to 14 weeks

  2. Volume of distribution (Vd/F)

    To determine the Vd/F of CTAP101 Capsules during and after repeated dosing

    Time frame: Up to 14 weeks

  3. Terminal elimination half-life (t1/2)

    To determine the t1/2 of CTAP101 Capsules during and after repeated dosing

    Time frame: Up to 14 weeks

  4. Incidence of treatment emergent adverse events (TEAE)

    TEAEs will be graded as mild, moderate, severe.

    Time frame: Up to 14 weeks

07

Study locations

1 of 5 sites recruiting
  • OPKO Site
    Kansas City, Missouri 64108, United States
    Not yet recruiting
  • OPKO Site
    Columbus, Ohio 43205, United States
    Not yet recruiting
  • OPKO Site
    Philadelphia, Pennsylvania 19104, United States
    Not yet recruiting
  • OPKO Site
    Greenville, South Carolina 29615, United States
    Recruiting
  • OPKO Site
    Madison, Wisconsin 53562, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 27, 2026
StartActual
Aug 5, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Aug 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494045
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Aug 5, 2026
Primary completion
Oct 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

OPKO Health
Contact
contact@opko.com
305-575-4100

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Modified-release Calcifediol Capsule

Start the discussion